Upgrade to SI Premium - Free Trial

ResMed (RMD) PT Raised to $321 at RBC Capital

May 1, 2026 5:55 AM
RBC Capital analyst Craig Wong-Pan raised the price target on ResMed (NYSE: RMD) to $321.00 (from $314.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change